About Stallergenes Greer
Stallergenes Greer is a company based in London (United Kingdom) founded in 2013 was acquired by Waypoint Capital in March 2019. Stallergenes Greer has completed 1 acquisition, including Adeo Health Science. Stallergenes Greer offers products and services including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine. Stallergenes Greer operates in a competitive market with competitors including HOOKIPA Pharma, Valneva, IgGenix, Immunomic Therapeutics and Alladapt, among others.
- Headquarter London, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stallergenes Greer Ltd
- Date of Incorporation 06 Dec, 2013
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stallergenes Greer
Stallergenes Greer offers a comprehensive portfolio of products and services, including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine.
Therapy to desensitize patients against allergens for better allergy control.
Methods for identifying allergens in respiratory and food allergies.
Tailored treatments addressing unmet needs in allergy care globally.
People of Stallergenes Greer
Unlock access to complete
Unlock access to complete
Leadership Team
10 people
Data Analysis and Operations Team
5 people
Software Development Team
5 people
Finance and Accounting
4 people
Operations Team
4 people
Product Management Team
3 people
Global Team
3 people
Responsable Team
3 people
Unlock access to complete
Funding Insights of Stallergenes Greer
Detailed funding history for Stallergenes Greer
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Stallergenes Greer
Stallergenes Greer has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include B-FLEXION.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
B-FLEXION is recognized as a private entrepreneurial investment firm.
|
Locked | Locked | Locked |
Investor details for Stallergenes Greer
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stallergenes Greer
Stallergenes Greer has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Adeo Health Science.
Investment portfolio details for Stallergenes Greer
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufactures proprietary baby food to safely introduce eight allergens.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Stallergenes Greer
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Stallergenes Greer
Detailed financials for Stallergenes Greer
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stallergenes Greer Comparisons
Peer comparison for Stallergenes Greer
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stallergenes Greer
Stallergenes Greer operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HOOKIPA Pharma, Valneva, IgGenix, Immunomic Therapeutics and Alladapt, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for food allergies are developed via antibody platforms.
|
|
| Locked | Locked | Locked |
Immunomic Therapeutics is engaged in developing nucleic acid immunotherapy platforms.
|
|
| Locked | Locked | Locked |
Therapeutics for treating food allergies are developed.
|
Detailed competitors of Stallergenes Greer
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stallergenes Greer
Complete news archive for Stallergenes Greer
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stallergenes Greer
Stallergenes Greer was founded in 2013.
Stallergenes Greer is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Michele Antonelli is the current CEO of Stallergenes Greer.
Stallergenes Greer is developing allergen immunotherapy (vaccine) for respiratory allergies. Its drug pipeline STAGR 320 (HDM) for Allergic Rhinitis (Phase 3 in EuropeUS and approved in Japan) and for HDM) Allergic Asthma (Phase 2); STAGR 120 for (Jap.Cedar) Allergic Rhinitis (Phase 2); JPSTAGR SAIL SLIT(Ragweed) Allergic Rhinitis (Phase 3).
Stallergenes Greer's top competitors include HOOKIPA Pharma, Valneva and IgGenix.
Stallergenes Greer offers Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine.
Stallergenes Greer has made 1 acquisition, including Adeo Health Science.
Stallergenes Greer has 1 investor. Key investors include B-FLEXION.